PE anti-human CD140a (PDGFRα)

Antibodies Single
Sony
16A1
Flow Cytometry
Mouse IgG1, κ
Human
NIH 3T3 cells transfected with human PDGFRα
2217530
$255.00

Description

The 16A1 monoclonal antibody recognizes human CD140a also known as the platelet-derived growth factor receptor, α polypeptide, PDGFR2, and PDGFRα. CD140a is a cell surface tyrosine kinase receptor for members of the platelet-derived growth factor family. The identity of the growth factor bound to the receptor determines whether the functional receptor is a homodimer or heterodimer composed of both PDGFR-α and -β. CD140a contains three immunoglobulin-like domains and a tyrosine kinase domain with a predicted molecular weight of approximately 123 kD. CD140a is widely expressed on a variety of mesenchymal-derived cells and has been implicated in the development of some tumors including basal cell carcinoma and gastric stromal cell tumors. Binding of A-chain containing PDGF molecules as well as protease-activated PDGF-C molecules can stimulate cell proliferation. CD140a has been shown to interact with a number of proteins including CRK, Grb2, Grb14, SHP2, and others as integrin β3, caveolin-1, and nexin sorting molecules. The PDGFRα is heavily phosphorylated on numerous tyrosine residues through both autophosphorylation and ligand-dependent processes. The 16A1 antibody has been shown to be useful for flow cytometric detection of CD140a.

Formulation

Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA (origin USA).

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. Test size products are transitioning from 20 microL to 5 microL per test. Please check your vial or your CoA to find the suggested use of this reagent per million cells in 100 microL staining volume or per 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

References

1. Miyazaki S et al. In:Leukocyte Typing VI Kishimoto et al. Eds, Garland Publishing Inc, New York 1998 pp 3-20.
2. Lottaz C, et al. 2010. Cancer Res. 70:2030. PubMed
3. Ricono JM, et al. 2009. Am. J. Physiol. Renal Physiol. 296:F406. (IF)
3. Guarnerio J, et al. 2015. Cancer Discov. 5:396. PubMed